...
首页> 外文期刊>International Journal of Pharmaceutical Sciences Review and Research >Evaluation of Aqueous Extract of Alphonsea sclerocarpa for in vivo and in vitro Antidiabetic Potentials in Wistar Rats” by
【24h】

Evaluation of Aqueous Extract of Alphonsea sclerocarpa for in vivo and in vitro Antidiabetic Potentials in Wistar Rats” by

机译:WISTAR大鼠体内体内和体外抗糖尿病潜力的Alphonsea Sclerocarpa水提取物评价“通过

获取原文
           

摘要

The purpose of current investigation was to investigate in vivo and in vitro anti-diabetic potentials of aqueous extract of Alphonsea sclerocarpa leaves against alloxan induced diabetes in albino rats. Two in vivo and one in vitro methods were performed for the evaluation of aqueous extract for antidiabetic activity. For in-vivo evaluation, diabetes was induced in albino rats by administering a single dose of alloxan. The study was designed to test the acute effect of aqueous extract of Alphonsea sclerocarpa (AEAS) to reduce blood glucose in OGTT. The chronic study of 21 days was performed against diabetic rats and blood glucose was determined at 1st , 7 th, 14th and 21st day. In chronic in vivo study, serum parameters insulin, urea, creatinine, total cholesterol, triglycerides, ALT and AST were also estimated at 21st day to determine the effects of aqueous and aqueous extracts on complications of diabetes mellitus. Glucose uptake by hemidiaphragm assay was performed to test the ability of extract to utilize glucose. In Oral Glucose Tolerance Test, standard glibenclamide and aqueous extract (200mg/kg and 400mg/kg) treated animals have shown significant reduction in blood glucose at 90 mins but at 120 mins. In chronic model the aqueous extract effectively reduced blood glucose levels (P<0.001) at 14th and 21st day of study in therapeutic groups and effect was comparable to that of standard. The extract could also significantly (P<0.001) reduce concentrations of SGOT, triglycerides, cholesterol and urea in serum and significantly (P 0.01). The presence of extract in glucose uptake assay could significantly increase utilization of the glucose by rat hemidiaphragm. The aqueous extract of Alphonsea sclerocarpa possess significant antidiabetic properties against alloxan induced diabetic animals.
机译:目前调查的目的是探讨体内和体外抗糖尿病患者的阿尔砜诱导糖尿病患者的体内患者的体内抗糖尿病潜力。在体内和一个体外方法进行了一种用于评估抗糖尿病活性的水性提取物。对于体内评估,通过施用单剂量的阿拉苏,在白化大鼠中诱导糖尿病。该研究旨在测试Alphonsea Sclerocarpa(AEA)水提取物的急性作用,以减少OGTT中的血糖。对糖尿病大鼠进行21天的慢性研究,并在第1,7〜第14天和第21天测定血糖。在第21天估计,在慢性研究中,血清参​​数胰岛素,尿素,尿素,总胆固醇,甘油三酯,ALT和AST估计,以确定水性和水性提取物对糖尿病并发症的影响。进行葡萄糖摄取通过血红蛋白测定进行测试以测试提取物利用葡萄糖的能力。在口腔葡萄糖耐量试验中,标准的Glibenclamide和含水提取物(200mg / kg和400mg / kg)处理的动物显示出90分钟的血糖显着降低,但在120分钟。在慢性模型中,水性提取物在治疗组中的第14次和第21天的研究中有效地降低了血糖水平(P <0.001),并且效果与标准的效果相当。提取物也可以显着(p <0.001)减少血清中SGOT,甘油三酯,胆固醇和尿素的浓度(p 0.01)。葡萄糖摄取测定中提取物的存在可显着提高葡萄糖的利用率通过大鼠血管斑。 Alphonsea Sclerocarpa的水性提取物对阿仑昔农诱导的糖尿病动物具有显着的抗糖尿病性能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号